Liwei Wang

4.4k total citations · 1 hit paper
55 papers, 1.4k citations indexed

About

Liwei Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Liwei Wang has authored 55 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Liwei Wang's work include CAR-T cell therapy research (10 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Liwei Wang is often cited by papers focused on CAR-T cell therapy research (10 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Liwei Wang collaborates with scholars based in China, United States and Netherlands. Liwei Wang's co-authors include Jianming Xu, Yuxian Bai, Shukui Qin, Guoping Sun, Zhehai Wang, Ying Cheng, Jianping Xiong, Leizhen Zheng, Nong Xu and Weijian Guo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Liwei Wang

50 papers receiving 1.4k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

2013 417 citations Shukui Qin, Jianming Xu et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Liwei Wang China	15	659	448	442	273	216	55	1.4k
Satoshi Matsusaka Japan	23	814 1.2×	298 0.7×	371 0.8×	334 1.2×	262 1.2×	133	1.5k
Ta‐Chung Chao Taiwan	22	724 1.1×	317 0.7×	485 1.1×	248 0.9×	139 0.6×	99	1.4k
Yilin Li China	20	633 1.0×	388 0.9×	276 0.6×	399 1.5×	140 0.6×	57	1.2k
Tae‐Yong Kim South Korea	26	1.4k 2.1×	626 1.4×	649 1.5×	424 1.6×	433 2.0×	125	2.4k
Byoung Yong Shim South Korea	18	596 0.9×	232 0.5×	359 0.8×	182 0.7×	248 1.1×	110	1.0k
Hirokazu Shoji Japan	23	815 1.2×	332 0.7×	527 1.2×	208 0.8×	720 3.3×	154	1.8k
Wenju Chang China	20	535 0.8×	403 0.9×	292 0.7×	249 0.9×	313 1.4×	79	1.3k
Yoon Ho Ko South Korea	23	514 0.8×	591 1.3×	375 0.8×	401 1.5×	173 0.8×	103	1.5k
Junzhong Lin China	19	629 1.0×	846 1.9×	311 0.7×	572 2.1×	294 1.4×	64	1.7k
Patrick M. Boland United States	26	1.3k 1.9×	374 0.8×	423 1.0×	351 1.3×	367 1.7×	110	2.1k

Countries citing papers authored by Liwei Wang

Since Specialization

Citations

This map shows the geographic impact of Liwei Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liwei Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liwei Wang more than expected).

Fields of papers citing papers by Liwei Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liwei Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liwei Wang. The network helps show where Liwei Wang may publish in the future.

Co-authorship network of co-authors of Liwei Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Liwei Wang. A scholar is included among the top collaborators of Liwei Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liwei Wang. Liwei Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Jiao, et al.. (2025). Comparison Between Low-Dose Esketamine and Dexmedetomidine on Postoperative Recovery Quality Among Patients Undergoing Humeral Trauma Surgery in Interscalene Brachial Plexus Block: A Randomized, Double-Blind, Controlled Trial. Drug Design Development and Therapy. Volume 19. 3645–3655.

Wang, Gang, et al.. (2025). Defect Size Quantification for Pipeline Dynamic MFL Detection via 3-D Dynamic Magnetic Dipole Forward Model. IEEE Transactions on Instrumentation and Measurement. 74. 1–10. 1 indexed citations

Wang, Liwei, Mengran Zhao, Lili Jiang, et al.. (2025). Avenanthramide C from underutilized oat glumes exhibits dual anti-oxidant and anti-thrombotic effects in oxidative damage and thrombosis models. Food & Function. 16(13). 5380–5392.

Trněný, Marek, Raúl Córdoba, Sven de Vos, et al.. (2025). ABCL-404: Epcoritamab + R-ICE in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Eligible For Autologous Stem Cell Transplantation (ASCT): EPCORE NHL-2. Clinical Lymphoma Myeloma & Leukemia. 25. S736–S736.

Liang, Yiyi, Xin Li, Qian Li, et al.. (2025). Upregulation of Lactobacillus spp . in gut microbiota as a novel mechanism for environmental eustress-induced anti-pancreatic cancer effects. Gut Microbes. 17(1). 2470372–2470372. 10 indexed citations

Zhao, Gang, Lei Wang, Hong Fang, & Liwei Wang. (2024). A review regarding the article ‘The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction—A systematic review’. Current Problems in Cardiology. 49(5). 102526–102526. 1 indexed citations

Falchi, Lorenzo, Joost S.P. Vermaat, Gerardo Musuraca, et al.. (2024). IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7. Clinical Lymphoma Myeloma & Leukemia. 24. S496–S497. 1 indexed citations

Falchi, Lorenzo, Anna Sureda, Sirpa Leppä, et al.. (2024). Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial. Blood. 144(Supplement 1). 342–342. 5 indexed citations

Falchi, Lorenzo, Joost S.P. Vermaat, Gerardo Musuraca, et al.. (2024). Epcoritamab with rituximab + lenalidomide (R²) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7.. Journal of Clinical Oncology. 42(16_suppl). 7014–7014. 3 indexed citations

10.

Xia, Qing, Tao Wu, Feng Wang, et al.. (2023). The safety and efficacy of cadonilimab in combination with AK117 (anti-CD47 antibody) plus chemotherapy as first-line treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology. 41(16_suppl). e16050–e16050. 4 indexed citations

11.

Wang, Yu, Yiyi Liang, Haiyan Xu, et al.. (2021). Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Discovery. 7(1). 36–36. 172 indexed citations

12.

Zou, Lu, Xuechuan Li, Jiujie Cui, et al.. (2021). Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study. BMC Cancer. 21(1). 818–818. 4 indexed citations

13.

Niu, Ningning, Ping Lu, Ruizhe He, et al.. (2019). Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia–mesenchymal transition during pancreatic carcinogenesis. Gut. 69(4). 715–726. 58 indexed citations

14.

Yang, Jian‐Yu, Junfeng Zhang, Yan‐Miao Huo, et al.. (2019). Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection. HPB. 22(1). 91–101. 31 indexed citations

15.

Zheng, Kai, Wenlong Mou, & Liwei Wang. (2017). Collect at Once, Use Effectively: Making Non-interactive Locally Private Learning Possible. International Conference on Machine Learning. 4130–4139. 2 indexed citations

16.

Xu, Rui‐Hua, Jin Li, Yuxian Bai, et al.. (2017). Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. Journal of Hematology & Oncology. 10(1). 63 indexed citations

17.

Liu, Xinyang, Shukui Qin, Zhichao Wang, et al.. (2017). Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. Journal of Hematology & Oncology. 10(1). 153–153. 66 indexed citations

18.

Li, Xinjian, Xu Qian, Li-Xia Peng, et al.. (2016). A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. Nature Cell Biology. 18(5). 561–571. 139 indexed citations

19.

Mellor, David, et al.. (2012). Stigma Toward Mental Illness. Journal of Cross-Cultural Psychology. 44(3). 352–364. 41 indexed citations

20.

Jiang, Yixing, Liwei Wang, Weida Gong, et al.. (2005). A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clinical & Experimental Metastasis. 21(8). 755–764. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact